Anti-C5aR antibody shows promise as immuno-oncology treatment
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
List view / Grid view
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
Our full gene-to-protein workflow can support your research for rapid protein production early during drug development so you can minimize changes from R&D to bioproduction.
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
8 October 2020 | By SPT Labtech
In this on-demand webinar, we explored the various methods of COVID-19 testing: qPCR, COVID-seq, antigen and antibody detection, and others. Coupling these assays with low volume, high speed automation has made great strides toward achieving the high-throughput testing essential to ending this pandemic.
An analysis of SARS-CoV-2 has allowed researchers to identify epitopes recognised by a large fraction of COVID-19 patients, with 10 that could be targeted by antibodies.
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.